Value of methylprednisolone infusion in patients wtih vertebral deposits

Pre-emptive value of methylpredinsolone intravenous infusion in patients with vertebral deposits. Double blinded randomized study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201211000432357

Enrollment

120

Registered

2012-10-08

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases Vertebral metasteses

Interventions

Preemptive methylprednisolone

Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: : One hundred twenty patients with class I-III Harrington classification of vertebral metastases included in the study admitted to the oncology department

Exclusion criteria

Exclusion criteria: Patients with any medical contraindications to corticosteroids, such as diabetes mellitus, uncontrolled hypertension, infection, thrombo-embolic disorders or active peptic ulcer were excluded from the study. Patients with a pathological fracture at the irradiated site, patients with other bone metastases and patients with visceral metastases at the time of radiotherapy were also excluded from the study.

Design outcomes

Primary

Measure	Time frame
Pain (VAS)	—

Secondary

Measure	Time frame
Motor function;Sensory function	—

Countries

Egypt

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026